— Specialty pharmaceutical company AcelRx Pharmaceuticals (NASDAQ: ACRX) reported fourth quarter 2019 loss of $0.18 per share vs. expected loss of $0.20 per share.
— Revenue was $0.48 million vs. $1.01 million expected.
— AcelRx also announced today about its acquisition of Tetraphase Pharmaceuticals for $14.4 million. This stock for stock deal is expected to close in the second quarter of 2020.
— AcelRx and Tetraphase have also entered into a co-promotion agreement, which will benefit both the teams in promoting multiple products, leveraging each company’s customer relationships, and creating efficiencies among commercial teams prior to the closing of the merger.
— AcelRx expects to achieve its previously communicated target of 465 REMS-certified facilities and formulary approvals by the end of 2020.
— The company expects quarterly combined R&D and SG&A expense in 2020 to range from $10 million to $13 million, depending on the quarter. This estimate includes approximately $1 million of non-cash stock-based compensation per quarter.
— ACRX stock was down more than 10% in the pre-market trading session.
Most Popular
Earnings Preview: What to look for when Netflix (NFLX) reports Q4 2025 results
Netflix, Inc. (NASDAQ: NFLX) is expected to report Q4 results on January 20, amid expectations for strong revenue and earnings growth. The company is navigating a shifting streaming landscape where
What to look for when United Airlines (UAL) reports its Q4 2025 earnings results
Shares of United Airlines (NASDAQ: UAL) stayed red on Thursday. The stock has gained 15% over the past three months. The airline is scheduled to report its earnings results for
Infographic: How Constellation Brands (STZ) performed in Q3 2026
Constellation Brands, Inc. (NYSE: STZ) reported net sales of $2.22 billion for the third quarter of 2026, down 10% year-over-year. Organic net sales were down 2%. Net income attributable to
